Lactoferricin
Research OnlyAlso known as: LFcinB, Lactoferricin B, LfcinB, LFcin
An antimicrobial peptide derived from lactoferrin, a protein found in milk and other secretions. Shows broad-spectrum antimicrobial activity in laboratory studies. Research focuses on potential applications in infectious disease, food safety, and cancer. Primarily studied preclinically with very limited human clinical data. Not approved as a therapeutic by any regulatory agency.
Research Statistics
Lactoferrin-derived antimicrobial peptide with international preclinical interest but very limited human data; membrane disruption mechanism is proposed but requires clinical validation.
Research Dossier
Overview
What is Lactoferricin and what does the research say?
Mechanism of Action
The proposed mechanisms of Lactoferricin are based primarily on in vitro and animal studies. Human mechanistic data is lacking.
How It Works (Simplified)
Lactoferricin acts as a natural antimicrobial by disrupting microbial membranes through several key mechanisms:
Cationic peptide (+8 charge) binds to negatively charged bacterial membranes via electrostatic attraction, initiating the killing process.
Amphipathic structure allows insertion into lipid bilayers, forming pores that cause membrane permeabilization and cell content leakage.
Human cells have neutral, cholesterol-rich membranes that resist attack, while bacterial and cancer cells have vulnerable anionic surfaces.
In cancer cells, triggers mitochondrial apoptosis pathway via ROS generation and caspase activation, independent of membrane lysis.
Scientific Pathways
Membrane Disruption Pathway (Antimicrobial)
LfcinB (+8 charge) → Electrostatic binding to anionic membrane → Membrane insertion
↓
Pore formation / Carpet model
↓
Membrane permeabilization → Cell deathApoptosis Pathway (Anticancer)
LfcinB → Phosphatidylserine targeting → ROS generation → Caspase-2 activation
↓
Mitochondrial depolarization → Caspase-9/3 → ApoptosisKey Research: Bellamy W et al. (1993) demonstrated rapid binding to bacterial surfaces with over 10 million molecules per cell, disrupting membrane permeability. PMID:8300449
Important Limitations
- Almost all research is preclinical (in vitro and animal studies)
- No human clinical trials have evaluated therapeutic efficacy
- Stability and delivery challenges limit in vivo applications
- Optimal formulation for systemic use remains unknown
- Pharmacokinetics in humans not characterized
Evidence-Chained Benefits
Evidence-Chained Benefits
Research findings linked to mechanisms and clinical outcomes
What to Expect
Timeline based on observations from published studies. Individual responses may vary.
Based on in vitro observations: Rapid binding to microbial membranes occurs within minutes. Bellamy et al. demonstrated over 10 million molecules binding per bacterial cell. Membrane permeabilization follows quickly. No human pharmacokinetic data available.
In vitro studies show bacterial killing within 1-4 hours at effective concentrations. Membrane disruption leads to loss of pH gradient and cell death. In vivo timeline in humans is completely unknown.
Animal model studies (mouse sepsis) showed survival benefits over several days of observation. Antifungal effects in mouse candidiasis model observed over treatment period. Human therapeutic timelines not established.
No long-term human studies exist. Stability, bioavailability, and sustained efficacy in humans are completely unknown. Research focus remains on developing stable formulations for potential therapeutic use.
Research-Based Observations
This timeline reflects observations from published clinical and preclinical studies. Individual responses may vary significantly. This is not a guarantee of effects or a dosing schedule. Consult qualified healthcare providers for personalized guidance.
Quality Checklist
Visual indicators to help evaluate Lactoferricin product quality
Good Signs (6 indicators)
Warning Signs (5 indicators)
Bad Signs (6 indicators)
For Research Evaluation Only
These quality indicators are general guidelines based on typical peptide characteristics. Professional laboratory testing (HPLC, mass spectrometry) provides definitive quality verification. This checklist is for initial visual evaluation only.
Peptide Interactions
Known and theoretical interactions when combining Lactoferricin with other peptides. Based on published research and mechanistic considerations.
LL-37
SynergisticBoth are cationic antimicrobial peptides with membrane-disrupting mechanisms. May have additive or synergistic antimicrobial effects through similar but complementary membrane targeting. No direct interaction studies available.
Thymosin-Alpha-1
CompatibleNon-overlapping mechanisms. Lactoferricin acts directly on microbial membranes while Thymosin Alpha-1 modulates adaptive immunity. Theoretical complementary benefits for immune support.
BPC-157
CompatibleDifferent mechanisms of action. Lactoferricin focuses on antimicrobial activity while BPC-157 targets tissue repair. No known contraindications.
GHK-Cu
CompatibleNon-overlapping mechanisms. GHK-Cu supports tissue remodeling via copper signaling while Lactoferricin provides antimicrobial activity. May complement each other in wound healing contexts.
Research Note: Interaction data is based on published literature, mechanistic understanding, and theoretical considerations. Most peptide combinations lack direct clinical study. This information is for educational purposes only and does not constitute medical advice. Always consult qualified healthcare providers.
References
Key Studies Cited
Full reference list available on request. All citations link to PubMed for verification.
Methodology Note
This dossier synthesizes available evidence from peer-reviewed literature, regulatory documents, and clinical trial registries. Evidence strength ratings follow a modified GRADE approach.
For complete methodology details, see our Methodology page.
Important Disclaimer
This dossier is for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider before making health decisions.
Get Research Alerts
New dossiers and major study summaries delivered to your inbox. Evidence-graded, citation-backed research you can trust.
No spam. Unsubscribe anytime.
Compare Lactoferricin
Related Peptides
Alpha-Defensins
HNP-1, HNP-2, HNP-3 +5 more
A family of small cationic antimicrobial peptides (29-35 amino acids) that are key components of innate immunity in humans. Produced primarily by neutrophils (HNP-1 to 4) and Paneth cells (HD-5, HD-6), they exhibit broad-spectrum antimicrobial activity and immunomodulatory functions. Well-characterized biochemically with extensive research, though therapeutic development faces challenges.
KPV
Lys-Pro-Val, Lysine-Proline-Valine, alpha-MSH(11-13) +1 more
A naturally occurring tripeptide derived from the C-terminus of alpha-melanocyte-stimulating hormone (alpha-MSH). Preclinical studies demonstrate potent anti-inflammatory effects via NF-kB inhibition, but no human clinical trials have been conducted. Research has focused on inflammatory bowel disease and skin inflammation models.
Kristagen
EDG, Glu-Asp-Gly, Immune tripeptide
A synthetic tripeptide (Glu-Asp-Gly) developed by Russian scientist Vladimir Khavinson, claimed to regulate thymus function and support immune cell differentiation. No Western clinical validation exists; research is limited to Russian preclinical studies.
Murepavadin
POL7080, RG7929
A first-in-class cyclic antimicrobial peptide targeting the LptD outer membrane protein of Pseudomonas aeruginosa. The first OMPTA (outer membrane protein targeting antibiotic) to reach clinical development. IV formulation discontinued due to nephrotoxicity; inhaled formulation continues Phase 3 development for cystic fibrosis and bronchiectasis patients.
Thymalin
Thymulin, Thymic Factor, Timalin +1 more
A thymic peptide complex developed in Russia and used clinically in the former Soviet Union for immunomodulation. Derived from calf thymus extract, it contains multiple peptides claimed to restore immune function. Approved in Russia since the 1970s but not recognized by Western regulatory agencies. Evidence comes primarily from Russian studies with limited Western replication.
Thymogen
Glu-Trp, EW dipeptide, Timogen +2 more
A synthetic dipeptide (glutamyl-tryptophan) developed in Russia as a defined successor to thymalin. Approved in Russia for immunomodulation with extensive Russian clinical literature. Represents an attempt to create a standardized, synthetic thymic peptide. Not approved by Western regulatory agencies.